Michele Boyce Ley, MD
Surgical Oncology · Tucson, AZNPI 1003855214
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for surgical oncology clinicians in AZ, where the typical reported total is $1,468.
Across 46 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$135
- Tactile Systems Technology Inc$101
- AstraZeneca$68
- Karyopharm Therapeutics Inc.$57
- Merck$51
- Genentech USA, Inc.$48
- plus $396 from 18 others
What the payments were for
- Food & beverage$856100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $135 |
| Tactile Systems Technology Inc | 4 | $101 |
| AstraZeneca | 4 | $68 |
| Karyopharm Therapeutics Inc. | 2 | $57 |
| Merck | 2 | $51 |
| Genentech USA, Inc. | 3 | $48 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $36 |
| Seagen Inc. | 1 | $30 |
| Bristol Myers Squibb | 1 | $30 |
| Merit Medical Systems Inc | 2 | $29 |
| Tempus AI, Inc | 2 | $29 |
| GSK | 1 | $27 |
| Eisai Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Hologic Inc | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Bayer | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Davol Inc. | 1 | $16 |
| Elucent Medical | 1 | $14 |
| Dova Pharmaceuticals | 1 | $13 |
How this compares
$856 in reported general payments places this provider in the 45th percentile of 29 surgical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 26 | $429 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $128 |
| Gabapentin | 15 | $103 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Tucson
- Taylor RiallTucson$6K
- Mohammad KhreissTucson$3K
- Grace HouTucson$59
- Faisal JehanTucson$48
- Jennifer ErdrichTucson$0
- David JacofskyPhoenix$11.3M
- Dipak RamkumarPhoenix$148K
- Mark GimbelGilbert$14K
- Zhi Ven FongPhoenix$7K
- Rohit SahaiChandler$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.